Evidence-based health benefits management: Strategies to optimize antiretroviral medication adherence and outcomes in HIV/AIDS

Journal of Managed Care Pharmacy

Volumn 12, Issue 7 SUPPL. B, 2006, Pages

  Zabinski, Richard A ^a,b  

^a UNITEDHEALTH GROUP   (United States)

^b Academy of Managed Care Pharmacy   (United States)

Author keywords

Antiretroviral therapy; Benefits management; HIV AIDS; Medication adherence

Indexed keywords

ANTIRETROVIRUS AGENT; CLARITHROMYCIN; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; ESCITALOPRAM; FENOFIBRATE; LAMIVUDINE; LANSOPRAZOLE; OMEPRAZOLE; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; CD4+ T LYMPHOCYTE; CONFERENCE PAPER; DIET RESTRICTION; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PRESCRIPTION; SIDE EFFECT; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; ARTICLE; EVIDENCE BASED MEDICINE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PHARMACY; UNITED STATES;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EVIDENCE-BASED MEDICINE; HIV SEROPOSITIVITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PHARMACEUTICAL SERVICES; UNITED STATES;

EID: 34548547314     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.s7-b.s12     Document Type: Conference Paper

References (10)

1. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40:158-63.
2. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-23.
3. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36:808-16.
4. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166:332-37.
5. Munk R. CPS info pack (suppl). POZ. July 1998.
6. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53:10-14.
7. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
8. Gallant JE, Staszewski S, Pozniak A, et al. Long-term efficacy and safety of tenofovir DF (TDF): a 144-week comparison versus stavudine (d4T) in antiretroviral-naïve patients. Presented at: XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Poster 4538.
9. Madruga JVR, Cassetti I, Suleiman JMAH, Zhong L, Enejosa J, Cheng AK. Improvement in lipoatrophy and lipid abnormalities following switch from stavudine (d4T) to tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-infected patients: a 48-week follow-up from Study 903e. Presented at: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil. Abstract TuPe2.2B12.
10. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60.